AbbVie (ABBV) revenue breakdown
By region, United States is the largest at 76% of fiscal 2025 revenue, growing 13% a year over 9 years.
Revenue by region
Fiscal years, as AbbVie reports them in its 10-K filings; fiscal 2025 total $61.2B.
| Regions | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $15.9B | $18.3B | $21.5B | $23.9B | $34.9B | $43.5B | $45.7B | $41.9B | $43.0B | $46.6B | 76% |
| All other countries | $3.9B | $4.1B | $3.9B | $3.6B | $4.0B | $4.8B | $4.8B | $5.0B | $5.4B | $5.8B | 9% |
| Germany | $1.1B | $1.2B | $1.3B | $909M | $1.0B | $1.2B | $1.3B | $1.3B | $1.5B | $1.7B | 3% |
| Japan | $770M | $764M | $1.6B | $1.2B | $1.2B | $1.1B | $956M | $1.0B | $1.1B | $1.3B | 2% |
| Canada | $624M | $659M | $730M | $813M | $1.2B | $1.4B | $1.2B | $1.1B | $1.1B | $1.2B | 2% |
| China | — | — | $152M | $195M | $471M | $857M | $912M | $950M | $917M | $1.0B | 2% |
| France | $713M | $730M | $783M | $695M | $797M | $936M | $787M | $780M | $776M | $806M | 1% |
| United Kingdom | $776M | $807M | $855M | $372M | $509M | $497M | $462M | $417M | $522M | $626M | 1% |
| Spain | $589M | $521M | $611M | $472M | $453M | $519M | $506M | $501M | $528M | $609M | 1% |
| Italy | $523M | $475M | $652M | $372M | $379M | $506M | $444M | $484M | $511M | $580M | 1% |
| Brazil | $355M | $410M | $350M | $359M | $406M | $368M | $430M | $439M | $464M | $478M | 1% |
| Australia | — | — | $350M | $395M | $527M | $533M | $508M | $472M | $463M | $459M | 1% |
| The Netherlands | $352M | $362M | — | — | — | — | — | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ABBV.
Open ABBV in InvestinglyQuestions
Where does AbbVie make its money?
In fiscal 2025, by region: United States $46.6B, All other countries $5.8B, Germany $1.7B, Japan $1.3B, Canada $1.2B.
From AbbVie's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.